Ajinomoto Bio-Pharma Services
We are part of Ajinomoto Bio-Pharma Services
In 2019, we integrated our product and service offerings with Ajinomoto Bio-Pharma Services, a fully integrated and global contract development and manufacturing organization (CDMO) providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.
Through its sites in Belgium, United States, Japan, and India, Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.
Learn more: AjiBio-Pharma.com
About Ajinomoto Group
Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group, which operates more than 100 manufacturing facilities and supporting offices globally.
The Ajinomoto Group is a global leader in amino acids, focused on the research, development and manufacture of high quality products for the pharmaceutical, specialty chemical, nutraceutical, sports nutrition, and health & beauty industries, as well as food seasoning and consumer food products.
Since 1908 and the discovery of umami, the fifth taste created by glutamic acid, the Ajinomoto Group has been supporting healthy lifestyles and greater wellness through wide-ranging applications of amino acid technologies. Dedicated to supporting the “Eat Well, Live Well” corporate message, the Ajinomoto Group is committed to providing sustainable and innovative solutions for global health and well-being.
Headquartered in Tokyo, Ajinomoto Co. is listed on the Tokyo Stock Exchange (TYO: 2802) and maintains operations in 35 countries and regions throughout the world. In fiscal 2017, Ajinomoto Co. had net sales of JPY 1,150.2 billion (USD 10.36 billion).
Learn more: Ajinomoto.com